Arrowhead Research Corp Down Big On Disappointing Hepatitis B Drug Data

Shares of Arrowhead Research Corp (NASDAQ: ARWR) are down sharply following tweets by Adam Feuerstein pointing to disappointing data on its Hepatitis B drug.

In case you're wondering, $ARWR selling off bc ARC-520 HepB data in #AASLD14 abstract just released are disappointing.

— Adam Feuerstein (@adamfeuerstein) October 8, 2014

$ARWR Sinks on Disappointing Hepatitis B Drug Data —> http://t.co/y8joTYbeDk

— Adam Feuerstein (@adamfeuerstein) October 8, 2014

Shares of Arrowhead Research Corp have been halted three times Wednesday, last trading at $5.76, down 54.4 percent.